All news (page 18)

• 

  2 June 2026

  Evonik opens Asia Beauty Science & Innovation Center in Shanghai

  First integrated beauty R&D hub in Asia, combining biotech-led ingredient development, formulation, testing and a customer experience space to support brands across China and Asia.
• 

  2 June 2026

  SOCAR and BCG sign cooperation on Caspian methane reduction

  Joint effort to fast-track methane cuts in Caspian oil and gas operations through projects, research and best-practice exchange, aiming for reductions by 2030.
• 

  2 June 2026

  ICARBON showcases advanced recycling at SET Tech Festival

  Presented advanced recycling and circular-economy solutions after SET100 selection; joined dena/Germany Trade & Invest workshop with 17 start-ups; visited EUREF‑Campus; pursuing international expansion.
• 

  2 June 2026

  Iberdrola awarded eight EU Innovation Fund projects for industrial heat electrification

  Eight industrial heat electrification projects will replace fossil heat with electric boilers, require about 240 GWh/year, mobilise 150 MW of renewables and secure ~€50m in aid.
• 

  2 June 2026

  VolagHy and Airbus co-finance Kuopio eSAF feasibility study

  Feasibility and financial modelling launched for a Kuopio flagship plant that aims to scale electro-based sustainable aviation fuel across the Nordics by 2040.
• 

  2 June 2026

  Roche: FDA accepts priority‑review NDA for giredestrant in ER‑positive early‑stage breast cancer

  FDA accepted priority NDA for oral SERD giredestrant as adjuvant in ER‑positive, HER2‑negative stage I–III breast cancer after phase III lidERA showed 30% iDFS risk reduction; PDUFA 30 Nov 2026.

• 

  2 June 2026

  INEOS Energy signs LNG supply deal with Marubeni for Asia deliveries from 2029

  DES LNG supply agreement to deliver into Asian markets, marking the firm's first Pacific Basin deliveries and expanding its diversified global LNG portfolio to meet rising regional demand.
• 

  2 June 2026

  WuXi Biologics Repeats CDP Supplier Engagement A-List

  Named to CDP SEA A List again for supplier climate engagement; praised for governance, Scope 3 disclosure, SBTi-aligned targets (net-zero by 2050), supplier audits, training and incentives.
• 

  2 June 2026

  EAS Batteries launches ultra‑high‑power 22 Ah LFP cell using Asahi Kasei Acetolyte

  22 Ah LFP cell using acetonitrile electrolyte achieves 2,550 W/kg continuous, 3,760 W/kg 2s pulse, ~2,400 cycles at 5C/100% DoD; samples in customer evaluation; 46xxx format planned.
• 

  2 June 2026

  Dow showcases AI thermal-management materials at COMPUTEX 2026

  Showcases liquid and immersion cooling fluids, coolants for cold plates and facility loops, thermal interface materials, silicone packaging and hot‑melt solutions; keynote on cooling AI data centers.
• 

  1 June 2026

  Solvay and Viridis LOI for Brazil-to-La Rochelle rare-earth supply

  LOI aims to deliver Brazilian rare-earth feedstock to a French separation plant by 2028, supporting magnet-grade Nd/Pr/Dy/Tb supply and industrial Dy/Tb separation by Sep 2026.
• 

  1 June 2026

  Amgen: EC approves IMDYLLTRA (tarlatamab) for ES‑SCLC after platinum therapy

  EU marketing authorisation for tarlatamab as monotherapy for extensive‑stage small cell lung cancer after progression on platinum‑based chemo; Phase 3 showed survival gain.
• 

  1 June 2026

  Genentech: FDA accepts NDA for giredestrant after positive Phase III adjuvant results in early ER‑positive breast cancer

  lidERA Phase III: giredestrant reduced invasive recurrence/death by 30% (HR 0.70); 3‑yr iDFS 92.4% vs 89.6%. Priority review; PDUFA Nov 30, 2026; well tolerated in >4,100 pts.
• 

  1 June 2026

  Honeywell names Jill Evanko to board

  Evanko, Duravant CEO with 25+ years in industrial and manufacturing (ex-Chart Industries CEO/CFO), joins as independent director and Audit Committee member; Notre Dame MBA.
• 

  1 June 2026

  TechnipFMC appoints Eric D. Mullins to board

  Eric D. Mullins, Chairman & CEO of Lime Rock Resources, joins the board effective June 1, 2026. He brings private equity, investment banking and public-board experience.
• 

  1 June 2026

  Fluor‑JGC JV Wins LNTP for LNG Canada Phase 2 Expansion

  Limited notice to proceed issued to begin early planning and key activities for the proposed Phase 2 expansion at the LNG Canada Kitimat export facility, supporting an FID that would double 14 Mtpa.
• 

  1 June 2026

  Moderna & Merck: 5‑Year Data — Intismeran plus KEYTRUDA Reduces Recurrence in High‑Risk Resected Stage III/IV Melanoma

  5-year Phase 2b follow-up: combination showed 49% RFS reduction (HR 0.51), 59% DMFS reduction (HR 0.411); OS trend (HR 0.471). Safety consistent; increased neoantigen-specific T‑cell clonotypes
• 

  1 June 2026

  Dow and Univar Solutions agree long-term distribution of Decarbia low‑carbon products

  Long-term deal expands access to low‑carbon products with verified PCF certificates across beauty, home care, food, pharma and industrial markets; aids Scope 3 reductions.
• 

  1 June 2026

  Momentive Names Jim Knaub CMO

  Effective June 1, the new CMO will lead global marketing, portfolio positioning, go‑to‑market and commercial enablement. Appointee joins from Dow with 24+ years; holds BS ChemE and an MBA.
• 

  1 June 2026

  bp starts non-associated gas production at ACG

  Commercial NAG started from West Chirag; well tests Qirmaki sands. Est. 4–6 Tcf recoverable; gas sent to Sangachal via existing infrastructure.
• 

  1 June 2026

  Linde 2025 Sustainability Report

  2025: 10% absolute GHG cut vs 2021; 50% electricity from low-carbon/renewables; customers avoided ~98M tCO2e; conserved 1B+ gallons water; diverted 200M lbs waste; supported ~2,100 orgs, 400k people.
• 

  1 June 2026

  OCI agrees to sell 50% of OCI Nitrogen to AGROFERT

  Divests 50% for ~€55m (subject to adjustments); buyer gains operational control. Put/call on remaining 50% exercisable from 2 years post-close at 7x two-year avg. pro-forma adj. EBITDA. Target H2 2027.
• 

  1 June 2026

  EEW updates Green Financing Framework; ISS-Corporate issues Second Party Opinion

  Publishes updated Green Financing Framework aligned with ICMA and LMA standards and the EU Taxonomy; covers energy, circular economy, carbon capture; independent SPO confirms quality
• 

  1 June 2026

  Vopak and Gasunie take conditional FID to extend EemsEnergyTerminal

  Conditional FID approved for extension of EemsEnergyTerminal, advancing LNG infrastructure; final FID pending permits. Customer contracts secured for LNG supply 2028–2036.
• 

  1 June 2026

  Equinor nomination committee recommends Jarle Roth as board chair

  Nomination committee proposes a new chair; recommends re-election of Anne Drinkwater (deputy) and five directors; Jon Erik Reinhardsen will resign. Election takes effect 1 July 2026 to June 2027.
• 

  1 June 2026

  Roche to present obesity‑portfolio data at ADA 2026

  Phase II data show enicepatide and petrelintide yield meaningful weight loss with good safety/tolerability. Both advance toward Phase III; a Phase II combo trial starts mid‑2026
• 

  1 June 2026

  CATL opens world’s largest energy-storage testbed for real-world validation

  10-ha, RMB3bn Xiamen facility offers open station-level validation across five labs: 35kV/100MVA grid sim, 1kV–500kV HV tests, 20MW combustion, -50–100°C climate chambers, EMC for 40-ft containers
• 

  31 May 2026

  Lilly: Retevmo reduces recurrence/death risk by 83% as adjuvant in early‑stage RET‑fusion NSCLC

  Phase 3 LIBRETTO-432 randomized 151 early-stage RET‑fusion NSCLC patients; at 24‑month follow‑up EFS rates 92% vs 61% (treatment vs placebo). Safety: elevated ALT/AST manageable with dose changes.
• 

  31 May 2026

  Johnson & Johnson PROTEUS Phase 3: Perioperative ERLEADA reduces risk of metastasis or death by 20%

  Perioperative apalutamide + ADT (6 months pre/post-surgery) raised pCR/MRD to 8.9% vs 1%, delayed need for further therapy >6 vs 3.5 years, met dual primary endpoints; safety profile as expected.
• 

  31 May 2026

  Johnson & Johnson: RYBREVANT FASPRO shows durable responses in advanced head and neck cancer

  Phase 1b/2 OrigAMI-4: subcutaneous amivantamab + hyaluronidase achieved 42% ORR (15% CR) in pretreated recurrent/metastatic HNSCC; median DOR not reached (11.8 mo FU); manageable safety.